Short Interest in Nuwellis, Inc. (NASDAQ:NUWE) Decreases By 29.2%

Nuwellis, Inc. (NASDAQ:NUWE) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 5,056 shares, a decline of 29.2% from the December 31st total of 7,144 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average trading volume of 159,143 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 159,143 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.4% of the shares of the stock are short sold.

Nuwellis Stock Down 10.0%

NASDAQ:NUWE opened at $3.77 on Friday. Nuwellis has a fifty-two week low of $1.71 and a fifty-two week high of $64.26. The firm’s 50 day moving average is $2.30 and its two-hundred day moving average is $4.19. The company has a market cap of $6.26 million, a P/E ratio of -0.03 and a beta of -0.19.

Nuwellis (NASDAQ:NUWE) last issued its earnings results on Wednesday, November 12th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($17.22) by $17.78. The business had revenue of $2.22 million during the quarter, compared to analysts’ expectations of $2.50 million. Nuwellis had a negative return on equity of 1,367.63% and a negative net margin of 202.83%. Research analysts forecast that Nuwellis will post -8.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on NUWE. Wall Street Zen cut shares of Nuwellis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid?overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low?shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.